Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib + PD-1 antibody with first-line chemotherapy in advanced non-small cell lung cancer
ChiCTR2500098340Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trilaciclib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Progression-free survival and Safety. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500098340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098340.